According to Novartis, Kesimpta is the first targeted B cell ... The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy.

“Novartis presented five Kesimpta abstracts at [ECTRIMS ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data.

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

I expect Kesimpta sales to grow nearly 30 ... With no meaningful pipeline events this year from Novartis, the investor focus is on commercial execution. And it should not be lacking in the third ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Novartis is scheduled to report results for ... neuroscience medicine Kesimpta and cardiovascular drug Entresto--the patent of which expires in 2025--are expected to be the key drivers in the ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Kesimpta, Kisqali, Cosentyx, Pluvicto and Leqvio. The top line beat the Zacks Consensus Estimate of $12.6 billion. Shares of Novartis have risen 14.6% year to date compared with the industry’s ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Volume contributed 12 percentage ...

Swiss pharma giant Novartis AG NVS reported better-than-expected ... driven by the momentum in Entresto, Kesimpta, Kisqali, Cosentyx, Pluvicto and Leqvio. The top line beat the Zacks Consensus ...